Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Aug 28:8:1635.
doi: 10.3389/fmicb.2017.01635. eCollection 2017.

Improved Vaccine against PRRSV: Current Progress and Future Perspective

Yuchen Nan  1 , Chunyan Wu  1 , Guoqian Gu  1 , Weiyao Sun  1 , Yan-Jin Zhang  2 , En-Min Zhou  1
Affiliations
Review

Improved Vaccine against PRRSV: Current Progress and Future Perspective

Yuchen Nan et al. Front Microbiol. .

Abstract

Porcine reproductive and respiratory syndrome virus (PRRSV), one of the most economically significant pathogens worldwide, has caused numerous outbreaks during the past 30 years. PRRSV infection causes reproductive failure in sows and respiratory disease in growing and finishing pigs, leading to huge economic losses for the swine industry. This impact has become even more significant with the recent emergence of highly pathogenic PRRSV strains from China, further exacerbating global food security. Since new PRRSV variants are constantly emerging from outbreaks, current strategies for controlling PRRSV have been largely inadequate, even though our understanding of PRRSV virology, evolution and host immune response has been rapidly expanding. Meanwhile, practical experience has revealed numerous safety and efficacy concerns for currently licensed vaccines, such as shedding of modified live virus (MLV), reversion to virulence, recombination between field strains and MLV and failure to elicit protective immunity against heterogeneous virus. Therefore, an effective vaccine against PRRSV infection is urgently needed. Here, we systematically review recent advances in PRRSV vaccine development. Antigenic variations resulting from PRRSV evolution, identification of neutralizing epitopes for heterogeneous isolates, broad neutralizing antibodies against PRRSV, chimeric virus generated by reverse genetics, and novel PRRSV strains with interferon-inducing phenotype will be discussed in detail. Moreover, techniques that could potentially transform current MLV vaccines into a superior vaccine will receive special emphasis, as will new insights for future PRRSV vaccine development. Ultimately, improved PRRSV vaccines may overcome the disadvantages of current vaccines and minimize the PRRS impact to the swine industry.

Keywords: PRRSV; PRRSV vaccine; cross-protection; interferon; modified live virus; porcine reproductive and respiratory syndrome virus.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Adams M. J., Lefkowitz E. J., King A. M., Harrach B., Harrison R. L., Knowles N. J., et al. (2016). Ratification vote on taxonomic proposals to the international committee on taxonomy of viruses (2016). Arch. Virol. 161 2921–2949. 10.1007/s00705-016-2977-6 - DOI - PMC - PubMed
    1. Albina E., Carrat C., Charley B. (1998). Interferon-alpha response to swine arterivirus (PoAV), the porcine reproductive and respiratory syndrome virus. J. Interferon Cytokine Res. 18 485–490. 10.1089/jir.1998.18.485 - DOI - PubMed
    1. An T. Q., Tian Z. J., Leng C. L., Peng J. M., Tong G. Z. (2011). Highly pathogenic porcine reproductive and respiratory syndrome virus, Asia. Emerg. Infect. Dis. 17 1782–1784. 10.3201/eid1709.110411 - DOI - PMC - PubMed
    1. Bai X., Wang Y., Xu X., Sun Z., Xiao Y., Ji G., et al. (2016). Commercial vaccines provide limited protection to NADC30-like PRRSV infection. Vaccine 34 5540–5545. 10.1016/j.vaccine.2016.09.048 - DOI - PubMed
    1. Balasuriya U. B., MacLachlan N. J. (2004). The immune response to equine arteritis virus: potential lessons for other arteriviruses. Vet. Immunol. Immunopathol. 102 107–129. 10.1016/j.vetimm.2004.09.003 - DOI - PubMed